| __timestamp | Amphastar Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 7461000 |
| Thursday, January 1, 2015 | 46974000 | 11960000 |
| Friday, January 1, 2016 | 47298000 | 13108000 |
| Sunday, January 1, 2017 | 50918000 | 17501000 |
| Monday, January 1, 2018 | 58044000 | 22472000 |
| Tuesday, January 1, 2019 | 63109000 | 24286000 |
| Wednesday, January 1, 2020 | 65157000 | 29689000 |
| Friday, January 1, 2021 | 68920000 | 38837000 |
| Saturday, January 1, 2022 | 66592000 | 47489000 |
| Sunday, January 1, 2023 | 80393000 | 53379000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xencor, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Amphastar's SG&A expenses have surged by approximately 99% from 2014 to 2023, reflecting a strategic expansion and investment in operational capabilities. In contrast, Xencor's expenses have increased by over 600% during the same period, indicating a rapid scale-up in their administrative and sales efforts. Notably, Amphastar consistently outspent Xencor, with 2023 figures showing Amphastar's expenses at 50% higher than Xencor's. This divergence highlights differing growth strategies and market positioning. As the pharmaceutical industry continues to evolve, these spending patterns offer insights into each company's priorities and future directions.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Apellis Pharmaceuticals, Inc. and Xencor, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.